Eli Lilly and Company

CEO Dave Ricks and Chief Scientific Officer Dan Skovronsky set the R&D investment strategy, with board oversight. CFO Anat Ashkenazi departed in 2024; Lucinda Meyer now serves as interim CFO. Capital allocation decisions for acquisitions and R&D projects go through an internal executive committee.

Lilly sources primarily through internal discovery labs in Indianapolis, San Diego, and Shanghai. It also licenses early-stage biotech molecules and executes bolt-on acquisitions like MorphiC in 2024. The company does not rely on external VC funds for deal flow.

Eli Lilly is a publicly traded corporation on the NYSE under ticker LLY. The Lilly Endowment holds a significant minority stake, providing long-term orientation, but the firm operates as a traditional pharma company, not a family office.

Lilly does not commit capital to external GP funds. All investment is direct into internal R&D programs, licensing deals, and M&A. It does not operate a venture capital arm, though it has made minority investments in companies like Sigilon Therapeutics.

Lilly invests across the drug development lifecycle: early-stage preclinical discovery through its labs, phase 1-3 clinical trials, and commercial-stage launches. Acquisitions focus on assets in phase 2 or later to de-risk pipeline additions.

Lilly does not invest in non-healthcare sectors like real estate, energy, or technology outside of health IT. It also generally avoids generic drugs and animal health after spinning off Elanco in 2018.

The Lilly Endowment is a separate charitable trust created by members of the Lilly family. It holds about 12% of Lilly's shares but has no operational control over the company. The endowment's grants do not fund Lilly's R&D; they focus on community, education, and religious causes.